Yes Koo...I am referring to Aducanumab (I'm assuming you checked the spelling)....just because it failed to improve MOCA scores doesn't mean Apabetalone will likewise fail....different MOAs.  As BDZ has pointed out in a subsquent post, Biogen's Mcap fell $16 billion USD after Aducanumab failed, which is a pretty good barometer for figuring out the pipeline value it was assigned by the market.

We'll know soon enough if Apabetalone improves MOCA scores in patients 70 years of age and older...something Biogen's drug failed to do.  If it does then we'll see what kind of valuation Resverlogix is given by the market....although I still view MACE RRR to be the ultimate lynch pin.

Biogen, Amarin, AbbVie....while their drugs can perhaps serve as a benchmark its still not apples to apples obviously....while Apabetalone might have points in common with Aducanumab, Vascepa and Humira, Resverlogix as a company does not imo compare well with the companies behind them.  

Like everyone I'm anxiously awaiting TLD so we can see where we're at.